# A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

> **NCT07145151** · PHASE2 · RECRUITING · sponsor: **The United Bio-Technology (Hengqin) Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis (MASH)

## Interventions

- **DRUG:** UBT251
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07145151
- **Lead sponsor:** The United Bio-Technology (Hengqin) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-06-04
- **Final completion:** 2027-08-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145151, "A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07145151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*